Michael Kinch – författare

The introduction of new medicines has dramatically improved the quantity and quality of individual and public health while contributing trillions of dollars to the global economy. In spite of these past successes — and indeed because of them — our ability to deliver new medicines may be quickly coming to an end. Moving from the beginning of the twentieth century to the present, A Prescription for Change reveals how changing business strategies combined with scientific hubris have altered the way new medicines are discovered, with dire implications for both health and the economy.To explain how we have arrived at this pivotal moment, Michael Kinch recounts the history of pharmaceutical and biotechnological advances in the twentieth century. Kinch relates stories of the individuals and organizations that built the modern infrastructure that supports the development of innovative new medicines. He shows that an accelerating cycle of acquisition and downsizing is cannibalizing that infrastructure Kinch demonstrates the dismantling of the pharmaceutical and biotechnological research and development enterprises could also provide opportunities to innovate new models that sustain and expand the introduction of newer and better breakthrough medicines in the years to come.

The introduction of new medicines has dramatically improved the quantity and quality of individual and public health while contributing trillions of dollars to the global economy. In spite of these past successes--and indeed because of them--our ability to deliver new medicines may be quickly coming to an end. Moving from the beginning of the twentieth century to the present, A Prescription for Change reveals how changing business strategies combined with scientific hubris have altered the way new medicines are discovered, with dire implications for both health and the economy.To explain how we have arrived at this pivotal moment, Michael Kinch recounts the history of pharmaceutical and biotechnological advances in the twentieth century. Kinch relates stories of the individuals and organizations that built the modern infrastructure that supports the development of innovative new medicines. He shows that an accelerating cycle of acquisition and downsizing is cannibalizing that infrastructure Kinch demonstrates the dismantling of the pharmaceutical and biotechnological research and development enterprises could also provide opportunities to innovate new models that sustain and expand the introduction of newer and better breakthrough medicines in the years to come.

Diffraction and background-limited operation at room temperature is the ultimate goal of the infrared physicist. The achievement of this goal is strongly dependent on the hybridization technology utilized in bonding the IR focal plane array to the Si ROIC. To this end, this book describes a disruptive architecture in the field of hybridization known as the vertically integrated photodiode. This technology, as applied specifically to HgCdTe, is described in detail by the author. However, it can in principle be applied to any IR semiconducting material system, provided suitable dry etch and passivation technologies exist. The limitations of the many current and varied IR architectures are discussed with regard to diffraction and background-limited performance as a function of operating temperature. Shockley–Read–Hall lifetime is found to be a major factor in these considerations, for which HgCdTe has no IR equal. However, a number of scientific and engineering challenges remain within the HgCdTe materials system before ultimate performance can be achieved. A discussion of those challenges, together with possible outcomes, constitutes the basis of this book.

If you have a child in school, you may have heard stories of long-dormant diseases suddenly reappearing—cases of measles, mumps, rubella, and whooping cough cropping up everywhere from elementary schools to Ivy League universities because a select group of parents refuse to vaccinate their children. Between Hope and Fear tells the remarkable story of vaccine-preventable infectious diseases and their social and political implications. While detailing the history of vaccine invention, Kinch reveals the ominous reality that our victories against vaccine-preventable diseases are not permanent—and could easily be undone. In the tradition of John Barry’s The Great Influenza and Siddhartha Mukherjee’s The Emperor of All Maladies, Between Hope and Fear relates the remarkable intersection of science, technology and disease that has helped eradicate many of the deadliest plagues known to man.

The introduction of new medicines has dramatically improved the quantity and quality of individual and public health while contributing trillions of dollars to the global economy. In spite of these past successes — and indeed because of them — our ability to deliver new medicines may be quickly coming to an end. Moving from the beginning of the twentieth century to the present, A Prescription for Change reveals how changing business strategies combined with scientific hubris have altered the way new medicines are discovered, with dire implications for both health and the economy.To explain how we have arrived at this pivotal moment, Michael Kinch recounts the history of pharmaceutical and biotechnological advances in the twentieth century. Kinch relates stories of the individuals and organizations that built the modern infrastructure that supports the development of innovative new medicines. He shows that an accelerating cycle of acquisition and downsizing is cannibalizing that infrastructure Kinch demonstrates the dismantling of the pharmaceutical and biotechnological research and development enterprises could also provide opportunities to innovate new models that sustain and expand the introduction of newer and better breakthrough medicines in the years to come.

The introduction of new medicines has dramatically improved the quantity and quality of individual and public health while contributing trillions of dollars to the global economy. In spite of these past successes — and indeed because of them — our ability to deliver new medicines may be quickly coming to an end. Moving from the beginning of the twentieth century to the present, A Prescription for Change reveals how changing business strategies combined with scientific hubris have altered the way new medicines are discovered, with dire implications for both health and the economy.To explain how we have arrived at this pivotal moment, Michael Kinch recounts the history of pharmaceutical and biotechnological advances in the twentieth century. Kinch relates stories of the individuals and organizations that built the modern infrastructure that supports the development of innovative new medicines. He shows that an accelerating cycle of acquisition and downsizing is cannibalizing that infrastructure Kinch demonstrates the dismantling of the pharmaceutical and biotechnological research and development enterprises could also provide opportunities to innovate new models that sustain and expand the introduction of newer and better breakthrough medicines in the years to come.

A fascinating history of our understanding and the treatment of cancer by one of the leading figures in the field—who is also a pioneer on the cusp of a breakthrough.For the first time since a 5th century Greek physician gave the name “cancer” (karkinos, in Greek) to a deadly disease first described in Egyptian Papyri, the medical world is near a breakthrough that could allow even the most conservative doctors and pragmatic patients to use the other “c word” – cure – in the same sentence as cancer. A remarkable series of events has brought us to this point, thanks in large part to a new ability to more efficiently harness the extraordinary power of the human immune system. The End of the Beginning is a remarkable history of cancer treatment and the evolution of our understanding of its dynamic interplay with the immune system. Through Michael Kinch’s personal experience as a cancer researcher and the head of the oncology program at a leading biotechnology company, we witness the incredible accumulation of breakthrough science and its rapid translation into life-saving technologies that have begun to dramatically increase the quality and quantity of life for cancer patients. In clear and accessible prose, Kinch details the remarkable history of people, science, technology and disease and presents thrilling next-generation technologies that hold the promise to eliminate cancer for some, and perhaps ultimately, for all.